Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 May 2017: Trial started, NCT03162731
  2. 22 May 2017: Trial registered, NCT03162731

The trials

NCT03162731: Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

State
Completed
Phase
Early Phase 1
People
24 taking part
Started
11 May 2017
Primary completion
27 Sep 2020
Arms
Treatment ( nivolumab, ipilimumab, radiation therapy)
Results
None posted
  1. 11 May 2017: Trial started
  2. 22 May 2017: Trial registered
  3. 16 Nov 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.